Background/Aims: Mutations in KCNJ11, the gene encoding the Kir6.2 subunit of pancreatic and neuronal KATP channels, are associated with a spectrum of neonatal diabetes diseases. Methods: Variant screening was used to identify the cause of neonatal diabetes, and continuous glucose monitoring was used to assess effectiveness of sulfonylurea treatment. Electrophysiological analysis of variant KATP channel function was used to determine molecular basis. Results: We identified a previously uncharacterized KCNJ11 mutation, c.988T>C [p.Tyr330His], in an Italian child diagnosed with sulfonylurea-resistant permanent neonatal diabetes and developmental delay (intermediate DEND). Functional analysis of recombinant KATP channels reveals that this mutation causes a drastic gain-of-function, due to a reduction in ATP inhibition. Further, we demonstrate that the Tyr330His substitution causes a significant decrease in sensitivity to the sulfonylurea, glibenclamide. Conclusions: In this subject, the KCNJ11 (c.988T>C) mutation provoked neonatal diabetes, with mild developmental delay, which was insensitive to correction by sulfonylurea therapy. This is explained by the molecular loss of sulfonylurea sensitivity conferred by the Tyr330His substitution and highlights the need for molecular analysis of such mutations.

1.
De Franco
E
,
Saint-Martin
C
,
Brusgaard
K
,
Knight Johnson
AE
,
Aguilar-Bryan
L
,
Bowman
P
,
Update of variants identified in the pancreatic β-cell KATP channel genes KCNJ11 and ABCC8 in individuals with congenital hyperinsulinism and diabetes
.
Hum Mutat
.
2020
;
41
:
884
905
. .
2.
Nichols
CG
.
Katp channels as molecular sensors of cellular metabolism
.
Nature
.
2006
;
440
:
470
6
. .
3.
Bowman
P
,
Sulen
Å
,
Barbetti
F
,
Beltrand
J
,
Svalastoga
P
,
Codner
E
,
Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to kcnj11 mutations: an International Cohort Study
.
Lancet Diabetes Endocrinol
.
2018
;
6
:
637
46
. .
4.
Bowman
P
,
Mathews
F
,
Barbetti
F
,
Shepherd
MH
,
Sanchez
J
,
Piccini
B
,
Long-term follow-up of glycemic and neurological outcomes in an international series of patients with sulfonylurea-treated abcc8 permanent neonatal diabetes
.
Diabetes care
.
2021
;
44
(
1
):
35
42
. .
5.
Masia
R
,
Koster
JC
,
Tumini
S
,
Chiarelli
F
,
Colombo
C
,
Nichols
CG
,
An atp-binding mutation (g334d) in kcnj11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes
.
Diabetes
.
2007
;
56
:
328
36
. .
6.
Shimomura
K
,
Girard
CA
,
Proks
P
,
Nazim
J
,
Lippiat
JD
,
Cerutti
F
,
Mutations at the same residue (r50) of kir6.2 (kcnj11) that cause neonatal diabetes produce different functional effects
.
Diabetes
.
2006
;
55
:
1705
12
. .
7.
Maejima
Y
,
Hasegawa
S
,
Horita
S
,
Kumamoto
K
,
Galvanovskis
J
,
Takenoshita
S
,
Water intake disorder in a dend syndrome afflicted patient with r50p mutation
.
Endocr J
.
2015
;
62
:
387
92
. .
8.
Pipatpolkai
T
,
Usher
S
,
Stansfeld
PJ
,
Ashcroft
FM
.
New insights into katp channel gene mutations and neonatal diabetes mellitus
.
Nat Rev Endocrinol
.
2020
;
16
:
378
93
. .
9.
Nikitina
I
,
Platonov
V
,
Kostareva
A
,
Skorodok
J
,
Grineva
E
.
2813-po case of permanent neonatal diabetes mellitus caused by y330h kcnj11 gene mutations: Genotype-phenotype correlations
.
Diabetes (Suppl)
.
2013
;
62
:
A685
A718
.
10.
Martin
GM
,
Kandasamy
B
,
DiMaio
F
,
Yoshioka
C
,
Shyng
SL
.
Anti-diabetic drug binding site in a mammalian katp channel revealed by cryo-em
.
Elife
.
2017
;
6
:
e31054
. .
11.
Lee KPK, Chen J, MacKinnon R. Molecular structure of human katp in complex with atp and adp. Elife. 2017; 6: e32481.
12.
Koster JC, Remedi MS, Dao C, Nichols CG. Atp and sulfonylurea sensitivity of mutant atp-sensitive k+ channels in neonatal diabetes: Implications for pharmacogenomic therapy. Diabetes. 2005; 54: 2645–54.
13.
de Wet
H
,
Proks
P
,
Lafond
M
,
Aittoniemi
J
,
Sansom
MS
,
Flanagan
SE
,
A mutation (r826w) in nucleotide-binding domain 1 of abcc8 reduces atpase activity and causes transient neonatal diabetes
.
EMBO Rep
.
2008
;
9
:
648
54
. .
14.
Iafusco
D
,
Bizzarri
C
,
Cadario
F
,
Pesavento
R
,
Tonini
G
,
Tumini
S
,
No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with kcnj11-associated permanent neonatal diabetes
.
Diabetologia
.
2011
;
54
:
2736
8
. .
15.
Coppack
SW
,
Lant
AF
,
McIntosh
CS
,
Rodgers
AV
.
Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus
.
Br J Clin Pharmacol
.
1990
;
29
:
673
84
. .
16.
Wambach
JA
,
Marshall
BA
,
Koster
JC
,
White
NH
,
Nichols
CG
.
Successful sulfonylurea treatment of an insulin-naive neonate with diabetes mellitus due to a kcnj11 mutation
.
Pediatr Diabetes
.
2010
;
11
(
4
):
286
8
.
17.
Schulz
M
,
Iwersen-Bergmann
S
,
Andresen
H
,
Schmoldt
A
.
Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics
.
Crit Care
.
2012
;
16
:
R136
. .
18.
Lung
DD
,
Gerona
RR
,
Wu
AH
,
Smollin
CG
.
Confirmed glyburide poisoning from ingestion of “street Valium”
.
J Emerg Med
.
2012
;
43
:
276
8
. .
19.
Sagen
JV
,
Raeder
H
,
Hathout
E
,
Shehadeh
N
,
Gudmundsson
K
,
Baevre
H
,
Permanent neonatal diabetes due to mutations in kcnj11 encoding kir6.2: patient characteristics and initial response to sulfonylurea therapy
.
Diabetes
.
2004
;
53
:
2713
8
. .
20.
Pearson
ER
,
Flechtner
I
,
Njolstad
PR
,
Malecki
MT
,
Flanagan
SE
,
Larkin
B
, ;
Neonatal Diabetes International Collaborative Group
.
Switching from insulin to oral sulfonylureas in patients with diabetes due to kir6.2 mutations
.
N Engl J Med
.
2006
;
355
:
467
77
.
21.
Shah
RP
,
Spruyt
K
,
Kragie
BC
,
Greeley
SA
,
Msall
ME
.
Visuomotor performance in kcnj11-related neonatal diabetes is impaired in children with dend-associated mutations and may be improved by early treatment with sulfonylureas
.
Diabetes care
.
2012
;
35
:
2086
8
. .
22.
Marshall
BA
,
Green
RP
,
Wambach
J
,
White
NH
,
Remedi
MS
,
Nichols
CG
.
Remission of severe neonatal diabetes with very early sulfonylurea treatment
.
Diabetes Care
.
2015
;
38
:
e38
9
. .
23.
Babenko
AP
,
Bryan
J
.
Sur-dependent modulation of katp channels by an n-terminal kir6.2 peptide. Defining intersubunit gating interactions
.
J Biol Chem
.
2002
;
277
:
43997
4004
. .
24.
Bryan
J
,
Vila-Carriles
WH
,
Zhao
G
,
Babenko
AP
,
Aguilar-Bryan
L
.
Toward linking structure with function in atp-sensitive k+ channels
.
Diabetes
.
2004
;
53
(
Suppl 3
):
S104
12
. .
25.
Masia
R
,
De Leon
DD
,
MacMullen
C
,
McKnight
H
,
Stanley
CA
,
Nichols
CG
.
A mutation in the tmd0-l0 region of f-1 (l225p) causes permanent neonatal diabetes mellitus (pndm)
.
Diabetes
.
2007
;
56
:
1357
62
. .
26.
Flanagan
SE
,
Clauin
S
,
Bellanné-Chantelot
C
,
de Lonlay
P
,
Harries
LW
,
Gloyn
AL
,
Update of mutations in the genes encoding the pancreatic beta-cell k(atp) channel subunits kir6.2 (kcnj11) and sulfonylurea receptor 1 (abcc8) in diabetes mellitus and hyperinsulinism
.
Hum Mutat
.
2009
;
30
:
170
80
. .
27.
Koster
JC
,
Sha
Q
,
Nichols
CG
.
Sulfonylurea and k(+)-channel opener sensitivity of k(atp) channels. Functional coupling of kir6.2 and sur1 subunits
.
J Gen Physiol
.
1999
;
114
:
203
13
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.